Assessment of Quality of Life of Children With Chronic Idiopathic Thrombocytopenic Purpura (Kid's ITP Tools)
KIT
1 other identifier
observational
183
1 country
1
Brief Summary
Assessment of quality of life of patient with chronic idiopathic thrombocytopenic purpura according to the type of treatment
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Apr 2017
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 12, 2017
CompletedStudy Start
First participant enrolled
April 12, 2017
CompletedFirst Posted
Study publicly available on registry
April 21, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
October 30, 2020
CompletedMarch 12, 2020
March 1, 2020
3.5 years
April 12, 2017
March 11, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
quality of life score according to type of treatment
quality of life score according to type of treatment
at inclusion visit
Secondary Outcomes (4)
number of hospitalisation and consults per year
at inclusion visit
description of general quality of life
at inclusion visit
description of general quality of life
at inclusion visit
description of awareness of parent and patient about Idiopathic thrombocytopenic purpura
at inclusion visit
Study Arms (1)
Idiopathic Thrombocytopenic Purpura
completion of questionnaire
Interventions
completion of questionnaire for patient and parent
Eligibility Criteria
Children with idiopathic thombocytopenic purpura, aged between 1 and 17 year
You may qualify if:
- children with Idiopathic thrombocytopenic purpura
- aged between 1 and 17 year
- Idiopathic thrombocytopenic purpura persistent at 12 months
- obtention of informed consent
You may not qualify if:
- Persistant/acute Idiopathic thrombocytopenic purpura
- concomittant chronic disease, stabilized or not
- Concomittant disease with life expectancy \< 1 year
- Person who have not belong to a social security scheme
- Secondary Idiopathic thrombocytopenic purpura
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
CHU d'Angers
Angers, 49933, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Isabelle Pellier, Pr
chu
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Target Duration
- 2 Months
- Sponsor Type
- OTHER GOV
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 12, 2017
First Posted
April 21, 2017
Study Start
April 12, 2017
Primary Completion
October 1, 2020
Study Completion
October 30, 2020
Last Updated
March 12, 2020
Record last verified: 2020-03
Data Sharing
- IPD Sharing
- Will not share